Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
80°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Genelux Corporation
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
August 14, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
July 30, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
May 24, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 23, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 27, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
November 14, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 07, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces New Chief Financial Officer
August 28, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
August 14, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
August 02, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
July 20, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
July 10, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
June 29, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
June 22, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces $18 Million Private Placement
June 12, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA)
May 25, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces $33 Million Private Placement
May 15, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
March 23, 2023
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Pricing of Initial Public Offering
January 25, 2023
From
Genelux Corporation
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.